a7837i
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of August 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Director/PDMR
Shareholding
16 August 2021 15:00
BST
Transactions by Persons Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announces that on 13 August 2021 the
Company's Chief Financial Officer, Dr Aradhana Sarin, was granted
an award over 19,414 Ordinary Shares of $0.25 each in the Company
(Ordinary Shares) under the AstraZeneca Performance Share Plan (the
AZPSP Award). The AZPSP Award has been granted on the same basis
(including as to performance measures) as for other employees who
participate in the 2021 AZPSP grant save that it has been pro-rated
to reflect she took up the role part way through the year. The
performance measures will be assessed over a three-year performance
period (1 January 2021 to 31 December 2023). The Ordinary Shares
granted under the AZPSP are subject to a two-year holding period
following the performance period, and are due to vest on the fifth
anniversary of grant.
Details of the performance measures attached to the AZPSP award can
be found in the Directors' Remuneration Report within the
AstraZeneca Annual Report and Form 20-F Information 2020, which is
available on the Company's website at www.astrazeneca.com/annualreport2020.
Also on 13 August 2021 Dr Sarin, was granted a one-off restricted
share award over 12,276 Ordinary Shares (the Restricted Share
Award). The Restricted Share Award has been granted in reliance on
LR 9.4.2 in connection with Dr Sarin's recruitment in order to
compensate her for the contractual severance rights that she
forfeited on taking up the role of Chief Financial Officer. The
award will normally only vest if Dr Sarin remains employed with the
Company through to 1 February 2023. Further detail, as
required by LR 9.4.2, will be set out in the Company's next Annual
Report and Accounts.
Further details are set out in the attached notification, made in
accordance with the requirements of the EU Market Abuse Regulation
(as it forms part of UK law pursuant to the European Union
(Withdrawal) Act 2018.
1.
|
Details of the person discharging managerial responsibilities /
person closely associated
|
(a)
|
Name
|
Aradhana Sarin
|
2.
|
Reason for the notification
|
(a)
|
Position/status
|
Chief Financial Officer
|
(b)
|
Initial notification/ Amendment
|
Initial notification
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
(a)
|
Name
|
AstraZeneca PLC
|
(b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
4.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
(a)
|
Description of the financial instrument, type of
instrument
|
Ordinary Shares of US$0.25 each in AstraZeneca
PLC
|
(b)
|
Identification code
|
GB0009895292
|
(c)
|
Nature of the transaction
|
Grants of compensatory restricted share award and ordinary course
award under the AstraZeneca Performance Share Plan
|
(d)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£82.09
|
31,690
|
(e)
|
Aggregated information
- Aggregated
volume
-
Price
|
Not applicable
|
(f)
|
Date of the transaction
|
13 August 2021
|
(g)
|
Place of the transaction
|
Outside a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
16 August 2021
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|